We’re starting our engines and revving up for The Progeria Research Foundation’s 11th International Scientific Workshop – RACE Progeria to the Cure!

PRF and Eiger BioPharmaceuticals announced today that a positive opinion has been issued from the EMA recommending approval for Zokinvy, a breakthrough treatment for Progeria and processing-deficient progeroid laminopathies (PL).

In May 2022, The Progeria Research Foundation in partnership with Brigham and Women’s Hospital, and Boston Children’s Hospital convened a specialized meeting of high-level cardiologists and researchers to discuss the urgency of cardiac stenosis in children with...

Check out our newsletter to read about FDA approval for the first-ever treatment for Progeria, learn how the research we fund has made remarkable progress toward the cure through genetic and RNA therapies, and get the scoop on all the exciting milestones we’re celebrating right now.

We’re thrilled to share that PRF has been awarded the highest 4-star Charity Navigator rating for our 8th straight year! CharityNavigator is the top evaluator of U.S.-based nonprofits, and this coveted 4-star rating is only awarded to 6% of the nonprofits evaluated....